Eguchi Kazuo, Kario Kazuomi, Shimada Kazuyuki
Department of Internal Medicine, Nishiarita Kyoritsu Hospital.
Nihon Rinsho. 2002 Oct;60(10):1987-91.
Angiotensin II plays a pathophysiological role for the development of cardiovascular disease. Angiotensin receptor blocker(ARB) is an antihypertensive drug that blocks the angiotensin II receptor. Recently, according to the reports of basic research, ARB has various cerebrovascular-protective-effects such as improvement of cerebrovascular auto-regulation, stroke prevention, reduction of brain edema, improvement of neurological outcome in cerebral ischemia and so on. There is no report of ARB being used for the acute stage of stroke. In an ongoing ACCESS(Acute Candesartan Cilexetil Evaluation in Stroke Survivors) trial, the ARB candesartan is being used to treat the acute stage of stroke. This trial is expected to clarify whether early treatment with candesartan during the acute stage of stroke is beneficial for the neurological outcome or prognosis.
血管紧张素II在心血管疾病的发展过程中发挥着病理生理作用。血管紧张素受体阻滞剂（ARB）是一种能阻断血管紧张素II受体的抗高血压药物。最近，根据基础研究报告，ARB具有多种脑血管保护作用，如改善脑血管自动调节功能、预防中风、减轻脑水肿、改善脑缺血的神经功能结局等。目前尚无ARB用于中风急性期的报道。在正在进行的ACCESS（中风幸存者急性坎地沙坦酯评价）试验中，ARB类药物坎地沙坦正被用于治疗中风急性期。该试验有望阐明在中风急性期早期使用坎地沙坦治疗是否对神经功能结局或预后有益。
